SOLEYNET

Live / Applied — Fourth extension granted (statement of use) (as of 05 Jan 2026)

What this means for you

Not registered yet, but its 16 Mar 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
97842857
Mark type
Stylized text
Filed
16 Mar 2023
Published for opposition
06 Feb 2024
Attorney of record
John L. Slafsky

Goods and services

  • Class 009 — Scientific and electric apparatus: downloadable computer software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; downloadable computer software, namely, software for use in generating, analyzing, and accessing data via advanced computational techniques, automation, infrastructure, artificial intelligence, and machine learning; downloadable computer software for discovering drugs, forecasting potential uses of drug compounds and generating insights from screening and analyzing molecules, all using advanced computational techniques, automation, infrastructure, artificial intelligence, machine learning, insilico, virtual screening, and generative chemistry; downloadable computer software for analyzing molecular data in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis for biotechnology and pharmaceutical companies
  • Class 042 — Scientific and technological services: drug discovery services; pharmaceutical research and development services; providing online non-downloadable computer software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; software as a service (SAAS) services featuring software for collecting, analyzing, reporting, and tracking data and information in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; providing online non-downloadable computer software for use in generating, analyzing, and accessing data via advanced computational techniques, automation, infrastructure, artificial intelligence, and machine learning; software as a service (SAAS) services featuring software for use in generating, analyzing, and accessing data via advanced computational techniques, automation, infrastructure, artificial intelligence, and machine learning; providing an online non-downloadable computer software platform for discovering drugs, forecasting potential uses of drug compounds and generating insights from screening and analyzing molecules, featuring software using advanced computational techniques, automation, infrastructure, artificial intelligence, machine learning, insilico, virtual screening, and generative chemistry; software as a service (SAAS) services featuring software for discovering drugs, forecasting potential uses of drug compounds and generating insights from screening and analyzing molecules, all using advanced computational techniques, automation, infrastructure, artificial intelligence, machine learning, insilico, virtual screening, and generative chemistry; providing an online non-downloadable computer software platform for analyzing molecular data in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis for biotechnology and pharmaceutical companies; software as a service (SAAS) services featuring software for analyzing molecular data in the fields of genetics, genomics, phenomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis for biotechnology and pharmaceutical companies; preclinical drug discovery and development services used for identifying, designing, and optimizing chemical compounds; pharmaceutical evaluation and preclinical evaluation of chemical series and chemical compounds in drug discovery; pharmaceutical drug development and discovery services, namely, identifying, designing, optimizing, and developing chemical series and chemical compounds via software using advanced computational techniques, automation, infrastructure, artificial intelligence, machine learning, computational modeling, high-throughput screening, medicinal chemistry, biology, pharmacology, insilico, virtual screening, and generative chemistry; providing an online searchable database in the fields of pharmaceuticals for scientific research purposes, in particular, pharmaceutical research and development, scientific research and development of pharmaceutical preparations, scientific development of new uses for pharmaceutical compounds, and scientific technical research; scientific research and development for forecasting the use of molecules as drug compounds and developing new uses for pharmaceutical compounds; research and development in the field of drug discovery and development, molecular screening, phenomics, genetics, genomics, biology, chemistry, molecular biology, pathology, phenotypic sciences, omics, and image-based analysis; drug discovery services, namely, phenotypic screening services for discovering novel molecules to develop into drug compounds

Owner

Prosecution history

  • 06 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 05 Jan 2026 — SOU EXTENSION 4 GRANTED
  • 05 Jan 2026 — SOU EXTENSION 4 FILED
  • 05 Jan 2026 — SOU TEAS EXTENSION RECEIVED
  • 23 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 22 Jul 2025 — SOU EXTENSION 3 GRANTED
  • 22 Jul 2025 — SOU EXTENSION 3 FILED
  • 22 Jul 2025 — SOU TEAS EXTENSION RECEIVED
  • 04 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 24 Jan 2025 — SOU EXTENSION 2 GRANTED
  • 23 Jan 2025 — SOU EXTENSION 2 FILED
  • 23 Jan 2025 — SOU TEAS EXTENSION RECEIVED
  • 19 Aug 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
  • 19 Aug 2024 — SOU EXTENSION 1 GRANTED
  • 19 Aug 2024 — SOU EXTENSION 1 FILED

View this trademark record on Marksy